@Sikekhuat There is no published news article stating which vaccine developer is associated with Inix. After so long since 4 September there are still no news updates although the article back in 4 September mentioned "A formal agreement on the deal is expected to be signed within weeks" . Most probably whatever vaccine deal that Inix was trying to arrange has failed or been abandoned.
The sinopharm hunan joint-venture with GI Healthcare Resources Sdn Bhd. The owners of GI Healthcare Resource Sdn. Bhd. are Tan Sri Lim Yew Loong (LYL Group), Tan Sri Leong Hoy Kum (Mah Sing), Sim Guan Yu and Rosli Dahlan (Lawyer).
Tan Sri Leong Hoy Kum is the founder of Mah Sing. It look like Mah Sing is in the Covid-19 vaccine loop. You all may take a look of the news from the following link.
Price have been pushed up and holding same as pharma and Dpharma, Expect the next catalyst then will explode up. suppose the next one is the "last" one to come, the main event..if not with a dessert. short-medium position.
Expect the peak of profit at 2 to 2.5 years after vaccine distribution started, thats at least 2 year positive annual report. Then, profits will dry out and there comes the banks, 5Gs (have biden really win, or will he be the same as trump in some other manners), semiconductors(especially) and Reits, if the dividends are still distributed same as before. Could be just bullshit but thats the best trend to go. The wait is worthwhile i think in short to medium hold.
The 10,000 doses of Sinopharm Vaccine to be sponsored is by Sinopharm and GI Healthcare Resources Sdn Bhd is merely to fulfill their corporate social responsibility (CSR) to donate 10,000 doses of Sinopharm Vaccine for emergency use of frontliners only, NOT FOR GENERAL PUBLIC. They will not be distributing the vaccines.
Please note that Emergency use is NOT the same as full approval. It is merely a form of conditional authorization of the vaccine to be used by specific targeted groups such as frontliners and vulnerable groups ONLY (and NOT FOR GENERAL PUBLIC). Emergency use authorization is just based on interim clinical trial results (pending the completion of phase III clinical trial). Once the phase III clinical trial of Sinopharm Vaccine is completed very soon, the complete clinical data of the vaccine can then be submitted to the Ministry of Health (MOH) for evaluation and approval. Upon receiving FULL APPROVAL of the vaccine by Ministry of Health (MOH), the vaccine can then be used for the GENERAL PUBLIC.
Kanger in collaboration with Zuellig Pharma and Kstar will be the ones distributing the vaccines to private and government hospitals and clinics.
Nah, help to promote this counter. Come and support Kanger too! Mari kita sama-sama huat!!
-------------------------- Solution Group targets to commence vaccine F&F facility by 2Q 2021
Solution Group Bhd is targeting to commence operation of a vaccine fill and finish (F&F) facility by the second quarter of 2021 (Q2 2021) or within a month of the facility’s successful establishment.
In a filing with Bursa Malaysia today, Solution Group said the setting up of the F&F facility is expected to be completed within four to six months from the commencement of work.
“As at the date of this announcement, the company is awaiting approval for the facility’s design plan from the National Pharmaceutical Regulatory Agency (NPRA) and has yet to commence work for the said facility,” it said.
On 14th September, the Group’s wholly owned manufacturing subsidiary Xepa-Soul Pattinson (M) Sdn Bhd secured renewal of its GMP status with the National Pharmaceutical Regulatory Authority (‘NPRA’) through a scheduled desktop audit. In the quarter, Apex Pharma Marketing Pte Ltd in Singapore increased its cold chain distribution capabilities with the expansion of its current 2-8 degrees C cold room and the acquisition of a -20 degrees C freezer room for pharmaceuticals, vaccines and biologics. Expansion of cold chain distribution capacity in Malaysia is scheduled for completion before the end of the current financial year. Review of Year To Date Performance versus Corresponding Period Last Year
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
limsingpoh9497
90 posts
Posted by limsingpoh9497 > 2020-11-18 21:36 | Report Abuse
TP for tomorrow?